Equities

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)189.00
  • Today's Change11.50 / 6.48%
  • Shares traded460.10k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

  • Revenue in HKD (TTM)1.67bn
  • Net income in HKD-621.35m
  • Incorporated2016
  • Employees1.42k
  • Location
    Sichuan Kelun-Biotech Biopharmaceutical Co LtdWenjiang District, Xinhua AvenueCHENGDU 610000ChinaCHN
  • Phone+86 2 867255028
  • Websitehttp://www.kelun-biotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
China Traditional Chinese Med Hldg CoLtd19.61bn1.39bn21.65bn17.30k15.570.94568.011.100.27620.27623.894.550.49851.472.161,133,463.003.844.605.857.0751.1857.077.709.771.489.830.177317.3526.699.9968.11-2.24-12.75--
WuXi XDC Cayman Inc2.30bn306.86m22.83bn1.18k67.963.8761.559.930.28050.28052.134.93------1,951,202.00--------26.35--13.35--4.03--0.0005--114.44--82.07------
Genscript Biotech Corp6.56bn-746.02m26.68bn6.94k--2.45--4.07-0.3541-0.35413.115.130.2837.595.45945,616.80-11.97-18.34-18.27-26.1548.7854.68-42.30-64.914.65--0.1694--34.1729.4457.91--17.14--
RemeGen Co Ltd1.16bn-1.64bn27.45bn3.62k--4.54--23.57-3.04-3.042.166.920.18640.40054.31322,168.00-26.17-18.66-31.75-23.7576.4881.94-140.43-102.881.31-64.320.2682--40.16148.65-51.30--59.07--
HUTCHMED (China) Ltd6.55bn787.45m30.19bn1.99k38.605.2935.354.610.89780.89787.626.550.72587.197.693,293,657.008.76-14.3513.36-20.4354.1236.5712.06-31.442.60--0.1038--96.5231.38127.93--38.65--
Sichuan Kelun-Biotech Biophrmctcl Co Ltd1.67bn-621.35m41.43bn1.42k--16.43--24.85-2.80-2.807.6111.50------1,178,228.00--------49.28---37.27--2.47-34.900.0251--91.62--6.81------
Akeso Inc4.90bn2.20bn43.25bn2.78k19.068.2719.178.832.622.625.856.040.61680.374915.981,763,326.0026.47-11.5931.40-13.8796.96--42.91-42.494.3919.180.3983--440.35337.43273.60--63.99--
Sino Biopharmaceutical Ltd28.35bn2.00bn58.47bn25.81k28.841.739.612.060.10780.13621.531.800.41042.315.731,098,745.007.2313.1113.3721.7480.9580.3717.6127.470.964911.830.247925.020.66574.63-10.29-27.22-7.181.15
Data as of May 10 2024. Currency figures normalised to Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.31%Per cent of shares held by top holders
HolderShares% Held
RTW Investments LPas of 10 Jul 20231.93m1.53%
Wellington Management Hong Kong Ltd.as of 27 Nov 20231.12m0.89%
China Universal Asset Management Co., Ltd.as of 10 Jul 20231.08m0.85%
Laurion Capital Management LPas of 10 Jul 2023939.60k0.74%
Norges Bank Investment Managementas of 31 Dec 2023635.40k0.50%
Fidelity Management & Research Co. LLCas of 31 Mar 2024359.06k0.28%
Wellington Management Co. LLPas of 31 Mar 2024285.68k0.23%
Janus Henderson Investors US LLCas of 31 Mar 2024155.70k0.12%
Nordea Investment Funds SAas of 28 Mar 2024140.30k0.11%
Genesis Investment Management LLPas of 30 Sep 202369.50k0.06%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.